Our Experts in the News
-
HHS OIG will review FDA’s approval of Biogen’s aducanumab
August 4, 2021
Drug Discovery & Development
-
Why FDA’s approval of aducanumab was unprecedented
July 23, 2021
Drug Discovery and Development
-
‘The FDA’s Decision Showed a Stunning Disregard for Science’
July 22, 2021
FAIR
-
FDA resumes biopharma inspections, but backlog may remain
July 22, 2021
Medical Marketing and Media
-
Florida is keeping a close watch on the FDA these days. Here’s why.
July 22, 2021
Tampa Bay Times
-
Doctor accused of groping, harassing 24 women in North Texas allowed to practice again
July 19, 2021
Fort Worth Star-Telegram
-
Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels
July 19, 2021
STAT
-
Booster shot debate takes centre stage as global Covid cases rise
July 17, 2021
Financial Times
-
Chris Bernadel on Haitian Assassination, Michael Carome on FDA Alzheimer’s Investigation
July 16, 2021
FAIR
-
The group Public Citizen wants FDA chief Janet Woodcock removed from her post
July 15, 2021
Washington Examiner
-
Will the new Alzheimer’s drug really cure the disease?
July 14, 2021
The Republic
-
Beleaguered FDA in talks for drug-company funding
July 13, 2021
MarketWatch
-
FDA head calls for inquiry into Alzheimer’s drug review
July 9, 2021
Associated Press
-
FDA Seeks to Probe Talks Between Staff and Biogen on Alzheimer’s Drug
July 9, 2021
Wall Street Journal
-
Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug
June 30, 2021
STAT
-
Exposé Showing 'Inappropriately Close' FDA, Biogen Collaboration Prompts Demand for IG Probe
June 30, 2021
Common Dreams
-
Controversial Approval Puts Lack of Permanent FDA Chief in Spotlight
June 23, 2021
Medscape
-
US medicines watchdog accused of cozy ties with Big Pharma
June 22, 2021
Financial Times
-
Alzheimer’s Drug Approval “Damages FDA Credibility,” Advocates Say
June 21, 2021
Filter
-
‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
June 16, 2021
STAT
Login
Subscribe